Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, MS, Daniil E Shabashvili, PhD, Jianping Li, MD, Luisa M Posada, Richard Lynn Bennett, PhD, Yang Feng, MS, Daphne Dupere Richer, PhD, Alberto Riva, PhD, Santhi Pondugula, PhD, Jonathan E. Bird, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2019) 134 (Supplement_1): 535.

https://doi.org/10.1182/blood-2019-128213

Published: 2019

Journal Articles

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Kartika Venugopal, MS, Jianping Li, MD, Daniil E Shabashvili, PhD, Luisa M Posada, Yang Feng, MS, Daphne Dupere-Richer, PhD, Aditya Bele, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2018) 132 (Supplement 1): 2643.

https://doi.org/10.1182/blood-2018-99-118708

Published: 2018

Journal Articles

Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.

Yi-Bin Chen, MD, Ephraim P. Hochberg, MD, Yang Feng, MS, MPH, Gabriela Motyckova, MD, Donna Neuberg, Sc.D., Thomas R. Spitzer, MD, David C. Fisher, MD, Ann S. LaCasce, MD

Blood (2007) 110 (11): 5124.

https://doi.org/10.1182/blood.V110.11.5124.5124

Published: 2007

Journal Articles

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Jennifer R. Brown, MD, PhD, Jonathan Friedberg, MD, Yang Feng, MS, Kimberly Phillips, BA, Jennifer C. Clark, MA, Paola dal Cin, PhD, Robin Joyce, MD, David C. Fisher, MD, Richard I. Fisher, MD, Ronald W. Takvorian, MD, Jane Liesveld, MD, Diana Marquis, BS, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2007) 110 (11): 1358.

https://doi.org/10.1182/blood.V110.11.1358.1358

Published: 2007

Journal Articles

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.

Jennifer R. Brown, MD, PhD, John G. Gribben, MD DPhil, Yang Feng, MS MPH, Donna Neuberg, DSc, Peter Mauch, MD, Lee M. Nadler, MD, Arnold S. Freedman, MD

Blood (2006) 108 (11): 3041.

https://doi.org/10.1182/blood.V108.11.3041.3041

Published: 2006

NARROW

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.

Email alerts

ASH Publications

American Society of Hematology

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only